Mitochondria in Cancer Stem Cells: From an Innocent Bystander to a Central Player in Therapy Resistance

References

• Ebben JD, Treisman DM, Zorniak M, Kutty RG, Clark PA, Kuo JS. The cancer stem cell paradigm: a new understanding of tumor development and treatment. Expert Opin Ther Targets. 2010;14(6):621–632. PMID: 20426697. doi:10.1517/14712598.2010.485186
   PubMed Web of Science ®Google Scholar
• Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645–648. PMID: 7509044. doi:10.1038/367645a0
   PubMed Web of Science ®Google Scholar
• Kleinsmith LJ, Pierce GB. Multipotentiality of Single Embryonal Carcinoma Cells. Cancer Res. 1964;24:1544–1551. PMID: 14234000.
   PubMed Web of Science ®Google Scholar
• Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730–737. PMID: 9212098. doi:10.1038/nm0797-730
   PubMed Web of Science ®Google Scholar
• Makino S. Further evidence favoring the concept of the stem cell in ascites tumors of rats. Ann N Y Acad Sci. 1956;63:818–830. PMID: 13314436. doi:10.1111/j.1749-6632.1956.tb50894.x
   PubMed Web of Science ®Google Scholar
• Stevens LC. The development of transplantable teratocarcinomas from intratesticular grafts of pre- and postimplantation mouse embryos. Dev Biol. 1970;21:364–382. PMID: 5436899. doi:10.1016/0012-1606(70)90130-2
   PubMed Web of Science ®Google Scholar
• Hermann PC, Bhaskar S, Cioffi M, Heeschen C. Cancer stem cells in solid tumors. Semin Cancer Biol. 2010;20:77–84. PMID: 20371287. doi:10.1016/j.semcancer.2010.03.004
   PubMed Web of Science ®Google Scholar
• Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983–3988. PMID: 12629218. doi:10.1073/pnas.0530291100
   PubMed Web of Science ®Google Scholar
• Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111–115. PMID: 17122771. doi:10.1038/nature05384
   PubMed Web of Science ®Google Scholar
• Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature. 2004;432(7015):396–401. PMID: 15549107. doi:10.1038/nature03128
   PubMed Web of Science ®Google Scholar
• Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67(3):1030–1037. PMID: 17283135. doi:10.1158/0008-5472.CAN-06-2030
   PubMed Web of Science ®Google Scholar
• Maitland NJ, Collins AT. Prostate cancer stem cells: a new target for therapy. J Clin Oncol. 2008;26:2862–2870. PMID: 18539965. doi:10.1200/JCO.2007.15.1472
   PubMed Web of Science ®Google Scholar
• Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. Nature. 2008;451:345–349. PMID: 18202660. doi:10.1038/nature06489
   PubMed Web of Science ®Google Scholar
• Zhang S, Balch C, Chan MW, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008;68:4311–4320. PMID: 18519691. doi:10.1158/0008-5472.CAN-08-0364
   PubMed Web of Science ®Google Scholar
• Ayob AZ, Ramasamy TS. Cancer stem cells as key drivers of tumour progression. J Biomed Sci. 2018;25:20. PMID: 29506506. doi:10.1186/s12929-018-0426-4
   PubMed Web of Science ®Google Scholar
• Yang L, Shi P, Zhao G, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020;5:8. PMID: 32296030. doi:10.1038/s41392-020-0110-5
   PubMed Web of Science ®Google Scholar
• Capp J-P. Cancer stem cells: from historical roots to a new perspective. J Oncol. 2019;2019:5189232. PMID: 31308849. doi:10.1155/2019/5189232
   PubMed Web of Science ®Google Scholar
• Shlush LI, Zandi S, Mitchell A, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014;506:328–333. PMID: 24522528. doi:10.1038/nature13038
   PubMed Web of Science ®Google Scholar
• Auffinger B, Tobias AL, Han Y, et al. Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy. Cell Death Differ. 2014;21:1119–1131. PMID: 24608791. doi:10.1038/cdd.2014.31
   PubMed Web of Science ®Google Scholar
• Hamerlik P, Lathia JD, Rasmussen R, et al. Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med. 2012;209:507–520. PMID: 22393126. doi:10.1084/jem.20111424
   PubMed Web of Science ®Google Scholar
• Huang R, Wang J, Zhong Y, et al. Mitochondrial DNA Deficiency in Ovarian Cancer Cells and Cancer Stem Cell-like Properties. Anticancer Res. 2015;35:3743–3753. PMID: 26124317.
   PubMed Web of Science ®Google Scholar
• Huang H, Zhang S, Li Y, et al. Suppression of mitochondrial ROS by prohibitin drives glioblastoma progression and therapeutic resistance. Nat Commun. 2021;12:3720. PMID: 34140524. doi:10.1038/s41467-021-24108-6
   PubMed Web of Science ®Google Scholar
• Ren Y, Liang H, Wang X, Cao Z, Ma Y, Liu X. Alterations in mitochondrial function and energy metabolism-related properties in thyroid cancer stem cells. Acta Biochim Pol. 2021;69:11–17. PMID: 34826218. doi:10.18388/abp.2020_5370
   PubMed Web of Science ®Google Scholar
• Kuntz EM, Baquero P, Michie AM, et al. Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells. Nat Med. 2017;23:1234–1240. PMID: 28920959. doi:10.1038/nm.4399
   PubMed Web of Science ®Google Scholar
• Chen J, Li Y, T-S Y, et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012;488:522–526. PMID: 22854781. doi:10.1038/nature11287
   PubMed Web of Science ®Google Scholar
• Qian ZR, Rubinson DA, Nowak JA, et al. Association of alterations in main driver genes with outcomes of patients with resected pancreatic ductal adenocarcinoma. JAMA Oncol. 2018;4:e173420. PMID: 29098284. doi:10.1001/jamaoncol.2017.3420
   PubMed Web of Science ®Google Scholar
• Shlush LI, Mitchell A, Heisler L, et al. Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature. 2017;547:104–108. PMID: 28658204. doi:10.1038/nature22993
   PubMed Web of Science ®Google Scholar
• Chang JC. Cancer stem cells: role in tumor growth, recurrence, metastasis, and treatment resistance. Medicine. 2016;95:S20–5. PMID: 27611935. doi:10.1097/MD.0000000000004766
   PubMed Web of Science ®Google Scholar
• Marzagalli M, Fontana F, Raimondi M, Limonta P. Cancer stem cells-key players in tumor relapse. Cancers. 2021;13:376. PMID: 33498502. doi:10.3390/cancers13030376
   PubMedGoogle Scholar
• Sehgal P, Chaturvedi P. Chromatin and cancer: implications of disrupted chromatin organization in tumorigenesis and its diversification. Cancers. 2023;15:466. PMID: 36672415. doi:10.3390/cancers15020466
   PubMed Web of Science ®Google Scholar
• Dave B, Mittal V, Tan NM, Chang JC. Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res. 2012;14:202. PMID: 22264257. doi:10.1186/bcr2938
   PubMed Web of Science ®Google Scholar
• Mani SA, Guo W, Liao M-J, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704–715. PMID: 18485877. doi:10.1016/j.cell.2008.03.027
   PubMed Web of Science ®Google Scholar
• Creighton CJ, Li X, Landis M, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A. 2009;106:13820–13825. PMID: 19666588. doi:10.1073/pnas.0905718106
   PubMed Web of Science ®Google Scholar
• Tanabe S, Quader S, Cabral H, Ono R. Interplay of EMT and CSC in Cancer and the Potential Therapeutic Strategies. Front Pharmacol. 2020;11:904. PMID: 32625096. doi:10.3389/fphar.2020.00904
   PubMed Web of Science ®Google Scholar
• Scheel C, Eaton EN, SH-J L, et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell. 2011;145:926–940. PMID: 21663795. doi:10.1016/j.cell.2011.04.029
   PubMed Web of Science ®Google Scholar
• Sun Y-F, Xu Y, Yang X-R, et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology. 2013;57:1458–1468. PMID: 23175471. doi:10.1002/hep.26151
   PubMed Web of Science ®Google Scholar
• Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1:313–323. PMID: 18371365. doi:10.1016/j.stem.2007.06.002
   PubMed Web of Science ®Google Scholar
• Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer. 2008;98:756–765. PMID: 18268494. doi:10.1038/sj.bjc.6604242
   PubMed Web of Science ®Google Scholar
• Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004;64:7011–7021. PMID: 15466194. doi:10.1158/0008-5472.CAN-04-1364
   PubMed Web of Science ®Google Scholar
• Peitzsch C, Nathansen J, Schniewind SI, Schwarz F, Dubrovska A. Cancer stem cells in head and neck squamous cell carcinoma: identification, characterization and clinical implications. Cancers. 2019;11:616. PMID: 31052565. doi:10.3390/cancers11050616
   PubMed Web of Science ®Google Scholar
• Koh E-Y, You J-E, Jung S-H, Kim P-H. Biological Functions and Identification of novel biomarker expressed on the surface of breast cancer-derived cancer stem cells via proteomic analysis. Mol Cells. 2020;43:384–396. PMID: 32235022. doi:10.14348/molcells.2020.2230
   PubMed Web of Science ®Google Scholar
• Phi LTH, Sari IN, Yang Y-G, et al. Cancer Stem Cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem Cells Int. 2018;2018:5416923. PMID: 29681949. doi:10.1155/2018/5416923
   PubMed Web of Science ®Google Scholar
• Walcher L, Kistenmacher A-K, Suo H, et al. Cancer stem cells-origins and biomarkers: perspectives for targeted personalized therapies. Front Immunol. 2020;11:1280. PMID: 32849491. doi:10.3389/fimmu.2020.01280
   PubMed Web of Science ®Google Scholar
• Dalerba P, Dylla SJ, Park I-K, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A. 2007;104:10158–10163. PMID: 17548814. doi:10.1073/pnas.0703478104
   PubMed Web of Science ®Google Scholar
• Zhang -S-S, Huang Z-W, L-X L, J-J F, Xiao B. Identification of CD200+ colorectal cancer stem cells and their gene expression profile. Oncol Rep. 2016;36:2252–2260. PMID: 27574016. doi:10.3892/or.2016.5039
   PubMed Web of Science ®Google Scholar
• Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8:755–768. PMID: 18784658. doi:10.1038/nrc2499
   PubMed Web of Science ®Google Scholar
• Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1:555–567. PMID: 18371393. doi:10.1016/j.stem.2007.08.014
   PubMed Web of Science ®Google Scholar
• Jiang F, Qiu Q, Khanna A, et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res. 2009;7:330–338. PMID: 19276181. doi:10.1158/1541-7786.MCR-08-0393
   PubMed Web of Science ®Google Scholar
• Li T, Su Y, Mei Y, et al. ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients’ outcome. Lab Invest. 2010;90:234–244. PMID: 20010854. doi:10.1038/labinvest.2009.127
   PubMed Web of Science ®Google Scholar
• Rasper M, Schäfer A, Piontek G, et al. Aldehyde dehydrogenase 1 positive glioblastoma cells show brain tumor stem cell capacity. Neuro Oncol. 2010;12:1024–1033. PMID: 20627895. doi:10.1093/neuonc/noq070
   PubMed Web of Science ®Google Scholar
• Su Y, Qiu Q, Zhang X, et al. Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer. Cancer Epidemiol Biomarkers Prev. 2010;19:327–337. PMID: 20142235. doi:10.1158/1055-9965.EPI-09-0865
   PubMed Web of Science ®Google Scholar
• Plaks V, Kong N, Werb Z. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell. 2015;16:225–238. PMID: 25748930. doi:10.1016/j.stem.2015.02.015
   PubMed Web of Science ®Google Scholar
• Pearce DJ, Taussig D, Simpson C, et al. Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells. 2005;23:752–760. PMID: 15917471. doi:10.1634/stemcells.2004-0292
   PubMed Web of Science ®Google Scholar
• Leng Z, Tao K, Xia Q, et al. Krüppel-like factor 4 acts as an oncogene in colon cancer stem cell-enriched spheroid cells. PLoS One. 2013;8:e56082. PMID: 23418515. doi:10.1371/journal.pone.0056082
   PubMed Web of Science ®Google Scholar
• Noh KH, Kim BW, Song K-H, et al. Nanog signaling in cancer promotes stem-like phenotype and immune evasion. J Clin Invest. 2012;122:4077–4093. PMID: 23093782. doi:10.1172/JCI64057
   PubMed Web of Science ®Google Scholar
• Lu H, Lyu Y, Tran L, et al. HIF-1 recruits NANOG as a coactivator for TERT gene transcription in hypoxic breast cancer stem cells. Cell Rep. 2021;36:109757. PMID: 34592152. doi:10.1016/j.celrep.2021.109757
   PubMed Web of Science ®Google Scholar
• Leis O, Eguiara A, Lopez-Arribillaga E, et al. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene. 2012;31:1354–1365. PMID: 21822303. doi:10.1038/onc.2011.338
   PubMed Web of Science ®Google Scholar
• Le Minh G, Esquea EM, Dhameliya TT, et al. Kruppel-like factor 8 regulates triple negative breast cancer stem cell-like activity. Front Oncol. 2023;13:1141834. PMID: 37152043. doi:10.3389/fonc.2023.1141834
   PubMed Web of Science ®Google Scholar
• Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The different mechanisms of cancer drug resistance: a brief review. Adv Pharm Bull. 2017;7:339–348. PMID: 29071215. doi:10.15171/apb.2017.041
   PubMed Web of Science ®Google Scholar
• Nagaraju GP, Bramhachari PV, Raghu G, El-Rayes BF. Hypoxia inducible factor-1α: its role in colorectal carcinogenesis and metastasis. Cancer Lett. 2015;366:11–18. PMID: 26116902. doi:10.1016/j.canlet.2015.06.005
   PubMed Web of Science ®Google Scholar
• Colwell N, Larion M, Giles AJ, et al. Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells. Neuro Oncol. 2017;19:887–896. PMID: 28339582. doi:10.1093/neuonc/now258
   PubMed Web of Science ®Google Scholar
• Seidel S, Garvalov BK, Wirta V, et al. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain. 2010;133:983–995. PMID: 20375133. doi:10.1093/brain/awq042
   PubMed Web of Science ®Google Scholar
• Louka M, Boutou E, Bakou V, et al. DNA damage response/repair in cancer stem cells — potential vs controversies. In: Advances in DNA Repair. IntechOpen; 2015.
   Google Scholar
• Ojha R, Bhattacharyya S, Singh SK. Autophagy in cancer stem cells: a potential link between chemoresistance, recurrence, and metastasis. Biores Open Access. 2015;4:97–108. PMID: 26309786. doi:10.1089/biores.2014.0035
   PubMed Web of Science ®Google Scholar
• Chen K, Zhang C, Ling S, Wei R, Wang J, Xu X. The metabolic flexibility of quiescent CSC: implications for chemotherapy resistance. Cell Death Dis. 2021;12:835. PMID: 34482364. doi:10.1038/s41419-021-04116-6
   PubMed Web of Science ®Google Scholar
• Safa AR. Resistance to drugs and cell death in cancer stem cells (CSCs). J Transl Sci. 2020;6:341. PMID: 35330670. doi:10.15761/jts.1000341
   PubMedGoogle Scholar
• Yadav AK, Desai NS. Cancer stem cells: acquisition, characteristics, therapeutic implications, targeting strategies and future prospects. Stem Cell Rev Rep. 2019;15:331–355. PMID: 30993589. doi:10.1007/s12015-019-09887-2
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756–760. PMID: 17051156. doi:10.1038/nature05236
   PubMed Web of Science ®Google Scholar
• Fang DD, Cao J, Jani JP, et al. Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line. Front Med. 2013;7:462–476. PMID: 23820871. doi:10.1007/s11684-013-0270-6
   PubMed Web of Science ®Google Scholar
• Li L, Clevers H. Coexistence of quiescent and active adult stem cells in mammals. Science. 2010;327:542–545. PMID: 20110496. doi:10.1126/science.1180794
   PubMed Web of Science ®Google Scholar
• Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011;17:313–319. PMID: 21386835. doi:10.1038/nm.2304
   PubMed Web of Science ®Google Scholar
• Luo M, J-F L, Yang Q, et al. Stem cell quiescence and its clinical relevance. World J Stem Cells. 2020;12:1307–1326. PMID: 33312400. doi:10.4252/wjsc.v12.i11.1307
   PubMed Web of Science ®Google Scholar
• Aponte PM, Caicedo A. Stemness in Cancer: stem Cells, Cancer Stem Cells, and Their Microenvironment. Stem Cells Int. 2017;2017:5619472. PMID: 28473858. doi:10.1155/2017/5619472
   PubMed Web of Science ®Google Scholar
• Kurki P, Vanderlaan M, Dolbeare F, Gray J, Tan EM. Expression of proliferating cell nuclear antigen (PCNA)/cyclin during the cell cycle. Exp Cell Res. 1986;166:209–219. PMID: 2874992. doi:10.1016/0014-4827(86)90520-3
   PubMed Web of Science ®Google Scholar
• Ye S, Ding Y-F, Jia W-H, et al. SET domain-containing protein 4 epigenetically controls breast cancer stem cell quiescence. Cancer Res. 2019;79:4729–4743. PMID: 31308046. doi:10.1158/0008-5472.CAN-19-1084
   PubMed Web of Science ®Google Scholar
• Gerdes J, Li L, Schlueter C, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol. 1991;138:867–873. PMID: 2012175.
   PubMed Web of Science ®Google Scholar
• Kobayashi A, Okuda H, Xing F, et al. Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J Exp Med. 2011;208:2641–2655. PMID: 22124112. doi:10.1084/jem.20110840
   PubMed Web of Science ®Google Scholar
• Abravanel DL, Belka GK, Pan T, et al. Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy. J Clin Invest. 2015;125:2484–2496. PMID: 25961456. doi:10.1172/JCI74883
   PubMed Web of Science ®Google Scholar
• Nguyen DX, Chiang AC, Zhang XH-F, et al. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell. 2009;138:51–62. PMID: 19576624. doi:10.1016/j.cell.2009.04.030
   PubMed Web of Science ®Google Scholar
• Yang A, Qin S, Schulte BA, Ethier SP, Tew KD, Wang GY. MYC Inhibition depletes cancer stem-like cells in triple-negative breast cancer. Cancer Res. 2017;77:6641–6650. PMID: 28951456. doi:10.1158/0008-5472.CAN-16-3452
   PubMedGoogle Scholar
• Lee SH, Reed-Newman T, Anant S, Ramasamy TS. Regulatory role of quiescence in the biological function of cancer stem cells. Stem Cell Rev Rep. 2020;16:1185–1207. PMID: 32894403. doi:10.1007/s12015-020-10031-8
   PubMed Web of Science ®Google Scholar
• Talukdar S, Bhoopathi P, Emdad L, Das S, Sarkar D, Fisher PB. Dormancy and cancer stem cells: an enigma for cancer therapeutic targeting. Adv Cancer Res. 2019;141:43–84. PMID: 30691685. doi:10.1016/bs.acr.2018.12.002
   PubMed Web of Science ®Google Scholar
• Coller HA, Sang L, Roberts JM. A new description of cellular quiescence. PLoS Biol. 2006;4:e83. PMID: 16509772. doi:10.1371/journal.pbio.0040083
   PubMed Web of Science ®Google Scholar
• Truskowski K, Amend SR, Pienta KJ. Dormant cancer cells: programmed quiescence, senescence, or both? Cancer Metastasis Rev. 2023;42:37–47. PMID: 36598661. doi:10.1007/s10555-022-10073-z
   PubMed Web of Science ®Google Scholar
• Jahanban-Esfahlan R, Seidi K, Manjili MH, Jahanban-Esfahlan A, Javaheri T, Zare P. Tumor cell dormancy: threat or opportunity in the fight against cancer. Cancers. 2019;11:1207. PMID: 31430951. doi:10.3390/cancers11081207
   PubMed Web of Science ®Google Scholar
• Hedley BD, Chambers AF. Tumor dormancy and metastasis. Adv Cancer Res. 2009;102:67–101. PMID: 19595307. doi:10.1016/S0065-230X(09)02003-X
   PubMed Web of Science ®Google Scholar
• Manjili MH. Tumor dormancy and relapse: from a natural byproduct of evolution to a disease state. Cancer Res. 2017;77:2564–2569. PMID: 28507050. doi:10.1158/0008-5472.CAN-17-0068
   PubMed Web of Science ®Google Scholar
• Páez D, Labonte MJ, Bohanes P, et al. Cancer dormancy: a model of early dissemination and late cancer recurrence. Clin Cancer Res. 2012;18:645–653. PMID: 22156560. doi:10.1158/1078-0432.CCR-11-2186
   PubMed Web of Science ®Google Scholar
• Mitra A, Mishra L, Li S. EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget. 2015;6:10697–10711. PMID: 25986923. doi:10.18632/oncotarget.4037
   PubMed Web of Science ®Google Scholar
• Cojoc M, Mäbert K, Muders MH, Dubrovska A. A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms. Semin Cancer Biol. 2015;31:16–27. PMID: 24956577. doi:10.1016/j.semcancer.2014.06.004
   PubMed Web of Science ®Google Scholar
• Kleffel S, Schatton T. Tumor dormancy and cancer stem cells: two sides of the same coin? Adv Exp Med Biol. 2013;734:145–179. PMID: 23143979. doi:10.1007/978-1-4614-1445-2_8
   PubMed Web of Science ®Google Scholar
• Dembinski JL, Krauss S. Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma. Clin Exp Metastasis. 2009;26:611–623. PMID: 19421880. doi:10.1007/s10585-009-9260-0
   PubMed Web of Science ®Google Scholar
• Lin W, Rajbhandari N, Liu C, et al. Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer. Cancer Res. 2013;73:1821–1830. PMID: 23467612. doi:10.1158/0008-5472.CAN-12-2067
   PubMed Web of Science ®Google Scholar
• Gao M-Q, Choi Y-P, Kang S, Youn JH, Cho N-H. CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene. 2010;29:2672–2680. PMID: 20190812. doi:10.1038/onc.2010.35
   PubMed Web of Science ®Google Scholar
• Roesch A, Fukunaga-Kalabis M, Schmidt EC, et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell. 2010;141:583–594. PMID: 20478252. doi:10.1016/j.cell.2010.04.020
   PubMed Web of Science ®Google Scholar
• Zeuner A, Francescangeli F, Contavalli P, et al. Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer. Cell Death Differ. 2014;21:1877–1888. PMID: 25034785. doi:10.1038/cdd.2014.105
   PubMed Web of Science ®Google Scholar
• Holtz MS, Forman SJ, Bhatia R. Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia. 2005;19:1034–1041. PMID: 15815728. doi:10.1038/sj.leu.2403724
   PubMed Web of Science ®Google Scholar
• Zanoni M, Bravaccini S, Fabbri F, Arienti C. Emerging roles of aldehyde dehydrogenase isoforms in anti-cancer therapy resistance. Front Med. 2022;9:795762. PMID: 35299840. doi:10.3389/fmed.2022.795762
   Web of Science ®Google Scholar
• Clark DW, Palle K. Aldehyde dehydrogenases in cancer stem cells: potential as therapeutic targets. Ann Transl Med. 2016;4:518. PMID: 28149880. doi:10.21037/atm.2016.11.82
   PubMed Web of Science ®Google Scholar
• Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid Proc Natl Acad Sci U S A. 1980;77(5):2936–2940. PMID: 6930676. doi:10.1073/pnas.77.5.2936
   PubMed Web of Science ®Google Scholar
• Lotan R. Different susceptibilities of human melanoma and breast carcinoma cell lines to retinoic acid-induced growth inhibition. Cancer Res. 1979;39(3):1014–1019. PMID: 427741.
   PubMed Web of Science ®Google Scholar
• Croker AK, Allan AL. Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44+ human breast cancer cells. Breast Cancer Res Treat. 2012;133(1):75–87. PMID: 21818590. doi:10.1007/s10549-011-1692-y
   PubMed Web of Science ®Google Scholar
• Chen Y-C, Chen Y-W, Hsu H-S, et al. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun. 2009;385(3):307–313. PMID: 19450560. doi:10.1016/j.bbrc.2009.05.048
   PubMed Web of Science ®Google Scholar
• Safa AR. Resistance to cell death and its modulation in cancer stem cells. Critical Reviews™ in Oncogenesis. 2016;21(3–4):203–219. PMID: 27915972. doi:10.1615/CritRevOncog.2016016976
   PubMedGoogle Scholar
• Yang L, Ren Y, Yu X, et al. ALDH1A1 defines invasive cancer stem-like cells and predicts poor prognosis in patients with esophageal squamous cell carcinoma. Mod Pathol. 2014;27(5):775–783. PMID: 24201124. doi:10.1038/modpathol.2013.189
   PubMed Web of Science ®Google Scholar
• Tomita H, Tanaka K, Tanaka T, Hara A. Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget. 2016;7(10):11018–11032. PMID: 26783961. doi:10.18632/oncotarget.6920
   PubMedGoogle Scholar
• He X, Gonzalez V, Tsang A, Thompson J, Tsang TC, Harris DT. Differential gene expression profiling of CD34 + CD133 + umbilical cord blood hematopoietic stem progenitor cells. Stem Cells Dev. 2005;14(2):188–198. PMID: 15910245. doi:10.1089/scd.2005.14.188
   PubMed Web of Science ®Google Scholar
• Forsberg EC, Prohaska SS, Katzman S, Heffner GC, Stuart JM, Weissman IL. Differential expression of novel potential regulators in hematopoietic stem cells. PLoS Genet. 2005;1(3):e28. PMID: 16151515. doi:10.1371/journal.pgen.0010028
   PubMed Web of Science ®Google Scholar
• Eirew P, Kannan N, Knapp DJHF, et al. Aldehyde dehydrogenase activity is a biomarker of primitive normal human mammary luminal cells. Stem Cells. 2012;30(2):344–348. PMID: 22131125. doi:10.1002/stem.1001
   PubMed Web of Science ®Google Scholar
• Sahovic EA, Colvin M, Hilton J, Ogawa M. Role for aldehyde dehydrogenase in survival of progenitors for murine blast cell colonies after treatment with 4-hydroperoxycyclophosphamide in vitro. Cancer Res. 1988;48(5):1223–1226.
   PubMed Web of Science ®Google Scholar
• Bunting KD, Townsend AJ. Protection by transfected rat or human class 3 aldehyde dehydrogenases against the cytotoxic effects of oxazaphosphorine alkylating agents in hamster V79 cell lines. J Biol Chem. 1996;271(20):11891–11896. doi:10.1074/jbc.271.20.11891
   PubMed Web of Science ®Google Scholar
• Safa AR. Drug and apoptosis resistance in cancer stem cells (CSCs): a puzzle with many pieces. Cancer Drug Resist. 2022;5(4):850–872. PMID: 36627897. doi:10.20517/cdr.2022.20
   PubMedGoogle Scholar
• Safa AR. c-FLIP, a master anti-apoptotic regulator. Exp Oncol. 2012;34(3):176–184. PMID: 23070002.
   PubMedGoogle Scholar
• Stantic M, Dong L-F, Zobalova R, Prokopova K, Neuzil J. Cancer cells with high expression of CD133 exert FLIP upregulation and resistance to TRAIL-induced apoptosis. Biofactors. 2008;34(3):231–235. PMID: 19734124. doi:10.1002/biof.5520340307
   PubMed Web of Science ®Google Scholar
• Zobalova R, McDermott L, Stantic M, Prokopova K, Dong L-F, Neuzil J. CD133-positive cells are resistant to TRAIL due to up-regulation of FLIP. Biochem Biophys Res Commun. 2008;373(4):567–571. PMID: 18590703. doi:10.1016/j.bbrc.2008.06.073
   PubMed Web of Science ®Google Scholar
• Ding L, Yuan C, Wei F, et al. Cisplatin restores TRAIL apoptotic pathway in glioblastoma-derived stem cells through up-regulation of DR5 and down-regulation of c-FLIP. Cancer Invest. 2011;29(8):511–520. PMID: 21877938. doi:10.3109/07357907.2011.605412
   PubMed Web of Science ®Google Scholar
• Gampa SC. Nano-TRAIL: a promising path to cancer therapy. Cancer Drug Resist. 2023;6(1):78–102. PMID: 37065863. doi:10.20517/cdr.2022.82
   PubMedGoogle Scholar
• Ivanisenko NV, Seyrek K, Hillert-Richter LK, et al. Regulation of extrinsic apoptotic signaling by c-FLIP: towards targeting cancer networks. Trends Cancer. 2022;8:190–209. PMID: 34973957. doi:10.1016/j.trecan.2021.12.002
   PubMed Web of Science ®Google Scholar
• Yoon MJ, Kang YJ, Kim IY, et al. Monensin, a polyether ionophore antibiotic, overcomes TRAIL resistance in glioma cells via endoplasmic reticulum stress, DR5 upregulation and c-FLIP downregulation. Carcinogenesis. 2013;34:1918–1928. PMID: 23615398. doi:10.1093/carcin/bgt137
   PubMed Web of Science ®Google Scholar
• Varfolomeev E, Goncharov T, Vucic D. Roles of c-IAP proteins in TNF receptor family activation of NF-κB signaling. Methods Mol Biol. 2015;1280:269–282. PMID: 25736754. doi:10.1007/978-1-4939-2422-6_15
   PubMedGoogle Scholar
• Ji J, Yu Y, Z-L L, et al. XIAP Limits autophagic degradation of Sox2 and Is a therapeutic target in nasopharyngeal carcinoma stem cells. Theranostics. 2018;8:1494–1510. PMID: 29556337. doi:10.7150/thno.21717
   PubMed Web of Science ®Google Scholar
• Wang Y-H, Scadden DT. Harnessing the apoptotic programs in cancer stem-like cells. EMBO Rep. 2015;16:1084–1098. PMID: 26253117. doi:10.15252/embr.201439675
   PubMed Web of Science ®Google Scholar
• Lee M-R, S-Y J, Mia-Jan K, Cho M-Y. Chemoresistance of CD133(+) colon cancer may be related with increased survivin expression. Biochem Biophys Res Commun. 2015;463:229–234. PMID: 26002465. doi:10.1016/j.bbrc.2015.05.031
   PubMed Web of Science ®Google Scholar
• Hu Y, Yagüe E, Zhao J, et al. Sabutoclax, pan-active BCL-2 protein family antagonist, overcomes drug resistance and eliminates cancer stem cells in breast cancer. Cancer Lett. 2018;423:47–59. PMID: 29496539. doi:10.1016/j.canlet.2018.02.036
   PubMed Web of Science ®Google Scholar
• Xu M, Gong A, Yang H, et al. Sonic hedgehog-glioma associated oncogene homolog 1 signaling enhances drug resistance in CD44(+)/Musashi-1(+) gastric cancer stem cells. Cancer Lett. 2015;369:124–133. PMID: 26276718. doi:10.1016/j.canlet.2015.08.005
   PubMed Web of Science ®Google Scholar
• Wang J, Liu X, Jiang Z, et al. A novel method to limit breast cancer stem cells in states of quiescence, proliferation or differentiation: use of gel stress in combination with stem cell growth factors. Oncol Lett. 2016;12:1355–1360. PMID: 27446437. doi:10.3892/ol.2016.4757
   PubMed Web of Science ®Google Scholar
• Veringa SJE, Biesmans D, van Vuurden DG, et al. In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma. PLoS One. 2013;8:e61512. PMID: 23637844. doi:10.1371/journal.pone.0061512
   PubMed Web of Science ®Google Scholar
• Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. 2018;18:452–464. PMID: 29643473. doi:10.1038/s41568-018-0005-8
   PubMed Web of Science ®Google Scholar
• Arneth B. Tumor Microenvironment. Medicina. 2019;56:15. PMID: 31906017. doi:10.3390/medicina56010015
   PubMed Web of Science ®Google Scholar
• Prieto-Vila M, Takahashi R-U, Usuba W, Kohama I, Ochiya T. Drug Resistance Driven by Cancer Stem Cells and Their Niche. Int J Mol Sci. 2017;18:2574. PMID: 29194401. doi:10.3390/ijms18122574
   PubMed Web of Science ®Google Scholar
• Li Y, Wang Z, Ajani JA, Song S. Drug resistance and Cancer stem cells. Cell Commun Signal. 2021;19:19. PMID: 33588867. doi:10.1186/s12964-020-00627-5
   PubMed Web of Science ®Google Scholar
• Diehn M, Cho RW, Lobo NA, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009;458:780–783. PMID: 19194462. doi:10.1038/nature07733
   PubMed Web of Science ®Google Scholar
• Desai A, Webb B, Gerson SL. CD133+ cells contribute to radioresistance via altered regulation of DNA repair genes in human lung cancer cells. Radiother Oncol. 2014;110:538–545. PMID: 24440048. doi:10.1016/j.radonc.2013.10.040
   PubMed Web of Science ®Google Scholar
• Mathews LA, Cabarcas SM, Hurt EM, Zhang X, Jaffee EM, Farrar WL. Increased expression of DNA repair genes in invasive human pancreatic cancer cells. Pancreas. 2011;40:730–739. PMID: 21633318. doi:10.1097/MPA.0b013e31821ae25b
   PubMed Web of Science ®Google Scholar
• Carruthers RD, Ahmed SU, Ramachandran S, et al. Replication stress drives constitutive activation of the DNA damage response and radioresistance in glioblastoma stem-like cells. Cancer Res. 2018;78:5060–5071. PMID: 29976574. doi:10.1158/0008-5472.CAN-18-0569
   PubMed Web of Science ®Google Scholar
• Wang Q-E. DNA damage responses in cancer stem cells: implications for cancer therapeutic strategies. World J Biol Chem. 2015;6:57–64. PMID: 26322164. doi:10.4331/wjbc.v6.i3.57
   PubMedGoogle Scholar
• Blanpain C, Mohrin M, Sotiropoulou PA, Passegué E. DNA-damage response in tissue-specific and cancer stem cells. Cell Stem Cell. 2011;8:16–29. PMID: 21211780. doi:10.1016/j.stem.2010.12.012
   PubMed Web of Science ®Google Scholar
• Liu Y, Zheng C, Huang Y, He M, Xu WW, Li B. Molecular mechanisms of chemo‐ and radiotherapy resistance and the potential implications for cancer treatment. MedComm. 2021;2:315–340. PMID: 34766149. doi:10.1002/mco2.55
   PubMedGoogle Scholar
• Cui Q, Wang J-Q, Assaraf YG, et al. Modulating ROS to overcome multidrug resistance in cancer. Drug Resist Updat. 2018;41:1–25. PMID: 30471641. doi:10.1016/j.drup.2018.11.001
   PubMed Web of Science ®Google Scholar
• Hwang IT, Chung YM, Kim JJ, et al. Drug resistance to 5-FU linked to reactive oxygen species modulator 1. Biochem Biophys Res Commun. 2007;359:304–310. PMID: 17537404. doi:10.1016/j.bbrc.2007.05.088
   PubMed Web of Science ®Google Scholar
• Kim E-K, Jang M, Song M-J, Kim D, Kim Y, Jang HH. Redox-mediated mechanism of chemoresistance in cancer cells. Antioxidants. 2019;8:471. PMID: 31658599. doi:10.3390/antiox8100471
   Web of Science ®Google Scholar
• Shen Y, Yang J, Zhao J, Xiao C, Xu C, Xiang Y. The switch from ER stress-induced apoptosis to autophagy via ROS-mediated JNK/p62 signals: a survival mechanism in methotrexate-resistant choriocarcinoma cells. Exp Cell Res. 2015;334:207–218. PMID: 25912909. doi:10.1016/j.yexcr.2015.04.010
   PubMed Web of Science ®Google Scholar
• Alimbetov D, Askarova S, Umbayev B, Davis T, Kipling D. Pharmacological targeting of cell cycle, apoptotic and cell adhesion signaling pathways implicated in chemoresistance of cancer cells. Int J Mol Sci. 2018;19:1690. PMID: 29882812. doi:10.3390/ijms19061690
   PubMed Web of Science ®Google Scholar
• Bailey HH. L-S,R-buthionine sulfoximine: historical development and clinical issues. Chem Biol Interact. 1998;111–112:239–254. PMID: 9679558. doi:10.1016/s0009-2797(97)00164-6
   PubMed Web of Science ®Google Scholar
• Jing X, Yang F, Shao C, et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 2019;18:157. PMID: 31711497. doi:10.1186/s12943-019-1089-9
   PubMed Web of Science ®Google Scholar
• O’Reilly D, Johnson P, Buchanan PJ. Hypoxia induced cancer stem cell enrichment promotes resistance to androgen deprivation therapy in prostate cancer. Steroids. 2019;152:108497. PMID: 31521707. doi:10.1016/j.steroids.2019.108497
   PubMed Web of Science ®Google Scholar
• Qian J, Rankin EB. Hypoxia-induced phenotypes that mediate tumor heterogeneity. Adv Exp Med Biol. 2019;1136:43–55. PMID: 31201715. doi:10.1007/978-3-030-12734-3_3
   PubMed Web of Science ®Google Scholar
• Yan Y, Liu F, Han L, et al. HIF-2α promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating Wnt and Notch pathways. J Exp Clin Cancer Res. 2018;37:256. PMID: 30340507. doi:10.1186/s13046-018-0925-x
   PubMed Web of Science ®Google Scholar
• Yang Y, Li X, Wang T, Guo Q, Xi T, Zheng L. Emerging agents that target signaling pathways in cancer stem cells. J Hematol Oncol. 2020;13:60. PMID: 32456660. doi:10.1186/s13045-020-00901-6
   PubMed Web of Science ®Google Scholar
• Espinosa-Sánchez A, Suárez-Martínez E, Sánchez-Díaz L, Carnero A. Therapeutic Targeting of Signaling Pathways Related to Cancer Stemness. Front Oncol. 2020;10:1533. PMID: 32984007. doi:10.3389/fonc.2020.01533
   PubMedGoogle Scholar
• Guerra F, Arbini AA, Moro L. Mitochondria and cancer chemoresistance. Biochim Biophys Acta Bioenerg. 2017;1858:686–699. PMID: 28161329. doi:10.1016/j.bbabio.2017.01.012
   PubMed Web of Science ®Google Scholar
• Bokil A, Sancho P. Mitochondrial determinants of chemoresistance. Cancer Drug Resist. 2019;2:634–646. PMID: 35582564. doi:10.20517/cdr.2019.46
   PubMedGoogle Scholar
• Porporato PE, Filigheddu N, Pedro JMB-S, Kroemer G, Galluzzi L. Mitochondrial metabolism and cancer. Cell Res. 2018;28:265–280. PMID: 29219147. doi:10.1038/cr.2017.155
   PubMed Web of Science ®Google Scholar
• Jin P, Jiang J, Zhou L, et al. Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management. J Hematol Oncol. 2022;15:97. PMID: 35851420. doi:10.1186/s13045-022-01313-4
   PubMed Web of Science ®Google Scholar
• Klein K, He K, Younes AI, et al. Role of mitochondria in cancer immune evasion and potential therapeutic approaches. Front Immunol. 2020;11:573326. PMID: 33178201. doi:10.3389/fimmu.2020.573326
   PubMed Web of Science ®Google Scholar
• Grasso D, Zampieri LX, Capelôa T, Van de Velde JA, Sonveaux P. Mitochondria in cancer. Cell Stress. 2020;4:114–146. PMID: 32548570. doi:10.15698/cst2020.06.221
   PubMedGoogle Scholar
• Bertram R, Gram Pedersen M, Luciani DS, Sherman A. A simplified model for mitochondrial ATP production. J Theor Biol. 2006;243:575–586. PMID: 16945388. doi:10.1016/j.jtbi.2006.07.019
   PubMed Web of Science ®Google Scholar
• Handy DE, Loscalzo J. Redox regulation of mitochondrial function. Antioxid Redox Signal. 2012;16:1323–1367. PMID: 22146081. doi:10.1089/ars.2011.4123
   PubMed Web of Science ®Google Scholar
• Tait SWG, Green DR. Mitochondria and cell signalling. J Cell Sci. 2012;125:807–815. PMID: 22448037. doi:10.1242/jcs.099234
   PubMed Web of Science ®Google Scholar
• Vakifahmetoglu-Norberg H, Ouchida AT, Norberg E. The role of mitochondria in metabolism and cell death. Biochem Biophys Res Commun. 2017;482:426–431. PMID: 28212726. doi:10.1016/j.bbrc.2016.11.088
   PubMed Web of Science ®Google Scholar
• Spinelli JB, Haigis MC. The multifaceted contributions of mitochondria to cellular metabolism. Nat Cell Biol. 2018;20:745–754. PMID: 29950572. doi:10.1038/s41556-018-0124-1
   PubMed Web of Science ®Google Scholar
• Vyas S, Zaganjor E, Haigis MC. Mitochondria and Cancer. Cell. 2016;166:555–566. PMID: 27471965. doi:10.1016/j.cell.2016.07.002
   PubMed Web of Science ®Google Scholar
• Facucho-Oliveira JM, Alderson J, Spikings EC, Egginton S, St John JC. Mitochondrial DNA replication during differentiation of murine embryonic stem cells. J Cell Sci. 2007;120:4025–4034. PMID: 17971411. doi:10.1242/jcs.016972
   PubMed Web of Science ®Google Scholar
• Wu Q, Tsai H-I, Zhu H, Wang D. The entanglement between mitochondrial DNA and Tumor metastasis. Cancers. 2022;14:1862. PMID: 35454769. doi:10.3390/cancers14081862
   PubMed Web of Science ®Google Scholar
• Liu Z, Shan S, Yuan Z, et al Mitophagy bridges DNA sensing with metabolic adaption to expand lung cancer stem-like cells. EMBO Rep. 2023;24:e54006. PMID: 36416244. doi:10.15252/embr.202154006
   PubMed Web of Science ®Google Scholar
• Masuike Y, Tanaka K, Makino T, et al. Esophageal squamous cell carcinoma with low mitochondrial copy number has mesenchymal and stem-like characteristics, and contributes to poor prognosis. PLoS One. 2018;13:e0193159. PMID: 29447301. doi:10.1371/journal.pone.0193159
   PubMed Web of Science ®Google Scholar
• Armstrong L, Tilgner K, Saretzki G, et al. Human induced pluripotent stem cell lines show stress defense mechanisms and mitochondrial regulation similar to those of human embryonic stem cells. Stem Cells. 2010;28:661–673. PMID: 20073085. doi:10.1002/stem.307
   PubMed Web of Science ®Google Scholar
• Paliwal S, Fiumera HL, Mohanty S. Stem cell plasticity and regenerative potential regulation through Ca2+-mediated mitochondrial nuclear crosstalk. Mitochondrion. 2021;56:1–14. PMID: 33059088. doi:10.1016/j.mito.2020.10.002
   PubMed Web of Science ®Google Scholar
• Cho YM, Kwon S, Pak YK, et al. Dynamic changes in mitochondrial biogenesis and antioxidant enzymes during the spontaneous differentiation of human embryonic stem cells. Biochem Biophys Res Commun. 2006;348:1472–1478. PMID: 16920071. doi:10.1016/j.bbrc.2006.08.020
   PubMed Web of Science ®Google Scholar
• Spurlock B, Gupta P, Basu MK, et al. New quantitative approach reveals heterogeneity in mitochondrial structure-function relations in tumor-initiating cells. J Cell Sci. 2019;132:jcs230755. PMID: 30910831. doi:10.1242/jcs.230755
   PubMed Web of Science ®Google Scholar
• Chakrabarty RP, Chandel NS. Mitochondria as Signaling organelles control mammalian stem cell fate. Cell Stem Cell. 2021;28:394–408. PMID: 33667360. doi:10.1016/j.stem.2021.02.011
   PubMed Web of Science ®Google Scholar
• Zheng -X-X, Chen -J-J, Sun Y-B, Chen T-Q, Wang J, S-C Y. Mitochondria in cancer stem cells: achilles heel or hard armor. Trends Cell Biol. 2023;33:708–727. PMID: 37137792. doi:10.1016/j.tcb.2023.03.009
   PubMed Web of Science ®Google Scholar
• Jun JC, Rathore A, Younas H, Gilkes D, Polotsky VY. Hypoxia-Inducible Factors and Cancer. Curr Sleep Med Rep. 2017;3:1–10. PMID: 28944164. doi:10.1007/s40675-017-0062-7
   PubMedGoogle Scholar
• Mu X, Zhao T, Xu C, et al. Oncometabolite succinate promotes angiogenesis by upregulating VEGF expression through GPR91-mediated STAT3 and ERK activation. Oncotarget. 2017;8:13174–13185. PMID: 28061458. doi:10.18632/oncotarget.14485
   PubMedGoogle Scholar
• van Uden P, Kenneth NS, Rocha S. Regulation of hypoxia-inducible factor-1alpha by NF-kappaB. Biochem J. 2008;412:477–484. PMID: 18393939. doi:10.1042/BJ20080476
   PubMed Web of Science ®Google Scholar
• Selak MA, Armour SM, MacKenzie ED, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. 2005;7:77–85. PMID: 15652751. doi:10.1016/j.ccr.2004.11.022
   PubMed Web of Science ®Google Scholar
• De Francesco EM, Sotgia F, Lisanti MP. Cancer stem cells (CSCs): metabolic strategies for their identification and eradication. Biochem J. 2018;475:1611–1634. PMID: 29743249. doi:10.1042/BCJ20170164
   PubMed Web of Science ®Google Scholar
• García-Heredia JM, Carnero A. Role of mitochondria in cancer stem cell resistance. Cells. 2020;9:1693. PMID: 32679735. doi:10.3390/cells9071693
   PubMedGoogle Scholar
• Shiota T, Traven A, Lithgow T. Mitochondrial biogenesis: cell-cycle-dependent investment in making mitochondria. Curr Biol. 2015;25:R78–80. PMID: 25602310. doi:10.1016/j.cub.2014.12.006
   PubMed Web of Science ®Google Scholar
• Jornayvaz FR, Shulman GI. Regulation of mitochondrial biogenesis. Essays Biochem. 2010;47:69–84. PMID: 20533901. doi:10.1042/bse0470069
   PubMed Web of Science ®Google Scholar
• Praharaj PP, Panigrahi DP, Bhol CS, et al. Mitochondrial rewiring through mitophagy and mitochondrial biogenesis in cancer stem cells: a potential target for anti-CSC cancer therapy. Cancer Lett. 2021;498:217–228. PMID: 33186655. doi:10.1016/j.canlet.2020.10.036
   PubMed Web of Science ®Google Scholar
• Dominy JE, Puigserver P. Mitochondrial biogenesis through activation of nuclear signaling proteins. Cold Spring Harb Perspect Biol. 2013;5:a015008. PMID: 23818499. doi:10.1101/cshperspect.a015008
   PubMed Web of Science ®Google Scholar
• Liu T, Ma Q, Li W, Hu Y, Yang J, Yao Q. Ubiquilin 1 suppresses the cancer stem cell-like traits of non-small cell lung cancer cells by regulating reactive oxygen species homeostasis. Bioengineered. 2021;12:7143–7155. PMID: 34546848. doi:10.1080/21655979.2021.1979353
   PubMed Web of Science ®Google Scholar
• X-Q Y, Li Q, Wang G-H, et al. Mitochondrial and energy metabolism-related properties as novel indicators of lung cancer stem cells. Int J Cancer. 2011;129:820–831. PMID: 21520032. doi:10.1002/ijc.25944
   PubMed Web of Science ®Google Scholar
• Mihaylova MM, Shaw RJ. The AMP-activated protein kinase (AMPK) signaling pathway coordinates cell growth, autophagy, & metabolism. Nat Cell Biol. 2011;13:1016–1023. PMID: 21892142. doi:10.1038/ncb2329
   PubMed Web of Science ®Google Scholar
• Ryoo I-G, Choi B-H, S-K K, Kwak M-K. High CD44 expression mediates p62-associated NFE2L2/NRF2 activation in breast cancer stem cell-like cells: implications for cancer stem cell resistance. Redox Biol. 2018;17:246–258. PMID: 29729523. doi:10.1016/j.redox.2018.04.015
   PubMed Web of Science ®Google Scholar
• Zhu J, Wang H, Sun Q, et al. Nrf2 is required to maintain the self-renewal of glioma stem cells. BMC Cancer. 2013;13:380. PMID: 23937621. doi:10.1186/1471-2407-13-380
   PubMed Web of Science ®Google Scholar
• Jia Y, Chen J, Zhu H, Jia Z-H, Cui M-H. Aberrantly elevated redox sensing factor Nrf2 promotes cancer stem cell survival via enhanced transcriptional regulation of ABCG2 and Bcl-2/Bmi-1 genes. Oncol Rep. 2015;34:2296–2304. PMID: 26324021. doi:10.3892/or.2015.4214
   PubMed Web of Science ®Google Scholar
• Kim B, Jung JW, Jung J, et al. PGC1α induced by reactive oxygen species contributes to chemoresistance of ovarian cancer cells. Oncotarget. 2017;8:60299–60311. PMID: 28947972. doi:10.18632/oncotarget.19140
   PubMedGoogle Scholar
• Sancho P, Burgos-Ramos E, Tavera A, et al. MYC/PGC-1α balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cells. Cell Metab. 2015;22:590–605. PMID: 26365176. doi:10.1016/j.cmet.2015.08.015
   PubMed Web of Science ®Google Scholar
• Lee K-M, Giltnane JM, Balko JM, et al. MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation. Cell Metab. 2017;26:633–647.e7. PMID: 28978427. doi:10.1016/j.cmet.2017.09.009
   PubMed Web of Science ®Google Scholar
• Chen C-L, Uthaya Kumar DB, Punj V, et al. NANOG metabolically reprograms tumor-initiating stem-like cells through tumorigenic changes in oxidative phosphorylation and fatty acid metabolism. Cell Metab. 2016;23:206–219. PMID: 26724859. doi:10.1016/j.cmet.2015.12.004
   PubMed Web of Science ®Google Scholar
• Murakami A, Takahashi F, Nurwidya F, et al. Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor. PLoS One. 2014;9:e86459. PMID: 24489728. doi:10.1371/journal.pone.0086459
   PubMed Web of Science ®Google Scholar
• Kim I-G, Lee J-H, Kim S-Y, Heo C-K, Kim R-K, Cho E-W. Targeting therapy-resistant lung cancer stem cells via disruption of the AKT/TSPYL5/PTEN positive-feedback loop. Commun Biol. 2021;4:778. PMID: 34163000. doi:10.1038/s42003-021-02303-x
   PubMed Web of Science ®Google Scholar
• Bleau A-M, Hambardzumyan D, Ozawa T, et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell. 2009;4:226–235. PMID: 19265662. doi:10.1016/j.stem.2009.01.007
   PubMed Web of Science ®Google Scholar
• Samanta D, Gilkes DM, Chaturvedi P, Xiang L, Semenza GL. Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells. Proc Natl Acad Sci U S A. 2014;111:E5429–5438. PMID: 25453096. doi:10.1073/pnas.1421438111
   PubMed Web of Science ®Google Scholar
• Peiris-Pagès M, Martinez-Outschoorn UE, Pestell RG, Sotgia F, Lisanti MP. Cancer stem cell metabolism. Breast Cancer Res. 2016;18:55. PMID: 27220421. doi:10.1186/s13058-016-0712-6
   PubMed Web of Science ®Google Scholar
• Gao C, Shen Y, Jin F, Miao Y, Qiu X. Cancer stem cells in small cell lung cancer cell line H446: higher dependency on oxidative phosphorylation and mitochondrial substrate-level phosphorylation than non-stem cancer cells. PLoS One. 2016;11:e0154576. PMID: 27167619. doi:10.1371/journal.pone.0154576
   PubMed Web of Science ®Google Scholar
• Pastò A, Bellio C, Pilotto G, et al. Cancer stem cells from epithelial ovarian cancer patients privilege oxidative phosphorylation, and resist glucose deprivation. Oncotarget. 2014;5:4305–4319. PMID: 24946808. doi:10.18632/oncotarget.2010
   PubMedGoogle Scholar
• Vlashi E, Lagadec C, Vergnes L, et al. Metabolic state of glioma stem cells and nontumorigenic cells. Proc Natl Acad Sci U S A. 2011;108:16062–16067. PMID: 21900605. doi:10.1073/pnas.1106704108
   PubMed Web of Science ®Google Scholar
• Janiszewska M, Suvà ML, Riggi N, et al. Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. Genes Dev. 2012;26:1926–1944. PMID: 22899010. doi:10.1101/gad.188292.112
   PubMed Web of Science ®Google Scholar
• Han S, Wei R, Zhang X, et al. CPT1A/2-mediated FAO enhancement-a metabolic target in radioresistant breast cancer. Front Oncol. 2019;9:1201. PMID: 31803610. doi:10.3389/fonc.2019.01201
   PubMed Web of Science ®Google Scholar
• Wang T, Fahrmann JF, Lee H, et al. JAK/STAT3-regulated Fatty Acid β-Oxidation is critical for breast cancer stem cell self-renewal and chemoresistance. Cell Metab. 2018;27:136–150.e5. PMID: 29249690. doi:10.1016/j.cmet.2017.11.001
   PubMed Web of Science ®Google Scholar
• Martínez-Reyes I, Chandel NS. Mitochondrial TCA cycle metabolites control physiology and disease. Nat Commun. 2020;11:102. PMID: 31900386. doi:10.1038/s41467-019-13668-3
   PubMed Web of Science ®Google Scholar
• Yi M, Li J, Chen S, et al. Emerging role of lipid metabolism alterations in Cancer stem cells. J Exp Clin Cancer Res. 2018;37:118. PMID: 29907133. doi:10.1186/s13046-018-0784-5
   PubMed Web of Science ®Google Scholar
• Camarda R, Zhou AY, Kohnz RA, et al. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nat Med. 2016;22:427–432. PMID: 26950360. doi:10.1038/nm.4055
   PubMed Web of Science ®Google Scholar
• Cardaci S, Ciriolo MR. TCA cycle defects and cancer: when metabolism tunes redox state. Int J Cell Biol. 2012;2012:161837. PMID: 22888353. doi:10.1155/2012/161837
   PubMedGoogle Scholar
• Ghosh P, Vidal C, Dey S, Zhang L. Mitochondria targeting as an effective strategy for cancer therapy. Int J Mol Sci. 2020;21:3363. PMID: 32397535. doi:10.3390/ijms21093363
   PubMed Web of Science ®Google Scholar
• Sciacovelli M, Frezza C. Oncometabolites: unconventional triggers of oncogenic signalling cascades. Free Radic Biol Med. 2016;100:175–181. PMID: 27117029. doi:10.1016/j.freeradbiomed.2016.04.025
   PubMed Web of Science ®Google Scholar
• Xiao M, Yang H, Xu W, et al. Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev. 2012;26:1326–1338. PMID: 22677546. doi:10.1101/gad.191056.112
   PubMed Web of Science ®Google Scholar
• Gasparre G, Kurelac I, Capristo M, et al. A mutation threshold distinguishes the antitumorigenic effects of the mitochondrial gene MTND1, an oncojanus function. Cancer Res. 2011;71:6220–6229. PMID: 21852384. doi:10.1158/0008-5472.CAN-11-1042
   PubMed Web of Science ®Google Scholar
• Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013;340:626–630. PMID: 23558169. doi:10.1126/science.1236062
   PubMed Web of Science ®Google Scholar
• Tilokani L, Nagashima S, Paupe V, Prudent J. Mitochondrial dynamics: overview of molecular mechanisms. Essays Biochem. 2018;62:341–360. PMID: 30030364. doi:10.1042/EBC20170104
   PubMed Web of Science ®Google Scholar
• Ferguson SM, De Camilli P. Dynamin, a membrane-remodelling GTPase. Nat Rev Mol Cell Biol. 2012;13:75–88. PMID: 22233676. doi:10.1038/nrm3266
   PubMed Web of Science ®Google Scholar
• Kraus F, Ryan MT. The constriction and scission machineries involved in mitochondrial fission. J Cell Sci. 2017;130:2953–2960. PMID: 28842472. doi:10.1242/jcs.199562
   PubMed Web of Science ®Google Scholar
• Pernas L, Scorrano L. Mito-morphosis: mitochondrial fusion, fission, and cristae remodeling as key mediators of cellular function. Annu Rev Physiol. 2016;78:505–531. PMID: 26667075. doi:10.1146/annurev-physiol-021115-105011
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhang J, Yu M, et al. Mitochondrial dynamics regulates migration and invasion of breast cancer cells. Oncogene. 2013;32:4814–4824. PMID: 23128392. doi:10.1038/onc.2012.494
   PubMed Web of Science ®Google Scholar
• Chen H, Chan DC. Mitochondrial dynamics in regulating the unique phenotypes of cancer and stem cells. Cell Metab. 2017;26:39–48. PMID: 28648983. doi:10.1016/j.cmet.2017.05.016
   PubMed Web of Science ®Google Scholar
• Wei M, Nurjanah U, Li J, et al. YY2-DRP1 axis regulates mitochondrial fission and determines cancer stem cell asymmetric division. Adv Sci. 2023:e2207349. PMID: 37300334. doi:10.1002/advs.202207349
   Web of Science ®Google Scholar
• Xie Q, Wu Q, Horbinski CM, et al. Mitochondrial control by DRP1 in brain tumor initiating cells. Nat Neurosci. 2015;18:501–510. PMID: 25730670. doi:10.1038/nn.3960
   PubMed Web of Science ®Google Scholar
• Peiris-Pagès M, Bonuccelli G, Sotgia F, Lisanti MP. Mitochondrial fission as a driver of stemness in tumor cells: mDIVI1 inhibits mitochondrial function, cell migration and cancer stem cell (CSC) signalling. Oncotarget. 2018;9:13254–13275. PMID: 29568355. doi:10.18632/oncotarget.24285
   PubMedGoogle Scholar
• Liu Z, Lei J, Wu T, et al. Lipogenesis promotes mitochondrial fusion and maintains cancer stemness in human NSCLC. JCI Insight. 2023;8:e158429. PMID: 36809297. doi:10.1172/jci.insight.158429
   PubMed Web of Science ®Google Scholar
• Civenni G, Bosotti R, Timpanaro A, et al. Epigenetic control of mitochondrial fission enables self-renewal of stem-like tumor cells in human prostate cancer. Cell Metab. 2019;30:303–318.e6. PMID: 31130467. doi:10.1016/j.cmet.2019.05.004
   PubMed Web of Science ®Google Scholar
• Zhou T-J, Zhang S-L, C-Y H, et al. Downregulation of mitochondrial cyclooxygenase-2 inhibits the stemness of nasopharyngeal carcinoma by decreasing the activity of dynamin-related protein 1. Theranostics. 2017;7:1389–1406. PMID: 28435473. doi:10.7150/thno.17647
   PubMed Web of Science ®Google Scholar
• Tang M, Yang M, Wu G, et al. Epigenetic induction of mitochondrial fission is required for maintenance of liver cancer-initiating cells. Cancer Res. 2021;81:3835–3848. PMID: 34049973. doi:10.1158/0008-5472.CAN-21-0436
   PubMed Web of Science ®Google Scholar
• Cai J, Wang J, Huang Y, et al. ERK/Drp1-dependent mitochondrial fission is involved in the MSC-induced drug resistance of T-cell acute lymphoblastic leukemia cells. Cell Death Dis. 2016;7:e2459. PMID: 27831567. doi:10.1038/cddis.2016.370
   PubMed Web of Science ®Google Scholar
• Cagin U, Duncan OF, Gatt AP, Dionne MS, Sweeney ST, Bateman JM. Mitochondrial retrograde signaling regulates neuronal function. Proc Natl Acad Sci U S A. 2015;112:E6000–6009. PMID: 26489648. doi:10.1073/pnas.1505036112
   PubMed Web of Science ®Google Scholar
• da Cunha FM, Torelli NQ, Kowaltowski AJ. Mitochondrial retrograde signaling: triggers, pathways, and outcomes. Oxid Med Cell Longev. 2015;2015:482582. PMID: 26583058. doi:10.1155/2015/482582
   PubMed Web of Science ®Google Scholar
• Rugarli EI, Langer T. Mitochondrial quality control: a matter of life and death for neurons. EMBO J. 2012;31:1336–1349. PMID: 22354038. doi:10.1038/emboj.2012.38
   PubMed Web of Science ®Google Scholar
• Biswas G, Adebanjo OA, Freedman BD, et al. Retrograde Ca2+ signaling in C2C12 skeletal myocytes in response to mitochondrial genetic and metabolic stress: a novel mode of inter-organelle crosstalk. EMBO J. 1999;18:522–533. PMID: 9927412. doi:10.1093/emboj/18.3.522
   PubMed Web of Science ®Google Scholar
• Arnould T, Michel S, Renard P. Mitochondria retrograde signaling and the upr mt: where are we in mammals? Int J Mol Sci. 2015;16:18224–18251. PMID: 26258774. doi:10.3390/ijms160818224
   PubMed Web of Science ®Google Scholar
• Jiang H-L, Sun H-F, Gao S-P, et al. SSBP1 suppresses TGFβ-driven epithelial-to-mesenchymal transition and metastasis in triple-negative breast cancer by regulating mitochondrial retrograde signaling. Cancer Res. 2016;76:952–964. PMID: 26676758. doi:10.1158/0008-5472.CAN-15-1630
   PubMed Web of Science ®Google Scholar
• Arbini AA, Guerra F, Greco M, et al. Mitochondrial DNA depletion sensitizes cancer cells to PARP inhibitors by translational and post-translational repression of BRCA2. Oncogenesis. 2013;2:e82. PMID: 24336406. doi:10.1038/oncsis.2013.45
   PubMed Web of Science ®Google Scholar
• Amuthan G, Biswas G, Ananadatheerthavarada HK, Vijayasarathy C, Shephard HM, Avadhani NG. Mitochondrial stress-induced calcium signaling, phenotypic changes and invasive behavior in human lung carcinoma A549 cells. Oncogene. 2002;21:7839–7849. PMID: 12420221. doi:10.1038/sj.onc.1205983
   PubMed Web of Science ®Google Scholar
• Guha M, Srinivasan S, Ruthel G, et al. Mitochondrial retrograde signaling induces epithelial-mesenchymal transition and generates breast cancer stem cells. Oncogene. 2014;33:5238–5250. PMID: 24186204. doi:10.1038/onc.2013.467
   PubMed Web of Science ®Google Scholar
• Gonzalez-Sanchez E, Marin JJG, Perez MJ. The expression of genes involved in hepatocellular carcinoma chemoresistance is affected by mitochondrial genome depletion. Mol Pharmaceutics. 2014;11:1856–1868. doi:10.1021/mp400732p
   PubMed Web of Science ®Google Scholar
• Shen L, Zhou L, Xia M, et al. PGC1α regulates mitochondrial oxidative phosphorylation involved in cisplatin resistance in ovarian cancer cells via nucleo-mitochondrial transcriptional feedback. Exp Cell Res. 2021;398:112369. PMID: 33220258. doi:10.1016/j.yexcr.2020.112369
   PubMed Web of Science ®Google Scholar
• Porporato PE, Payen VL, Pérez-Escuredo J, et al. A mitochondrial switch promotes tumor metastasis. Cell Rep. 2014;8:754–766. PMID: 25066121. doi:10.1016/j.celrep.2014.06.043
   PubMed Web of Science ®Google Scholar
• Ding W-X, Yin X-M. Mitophagy: mechanisms, pathophysiological roles, and analysis. Biol Chem. 2012;393:547–564. PMID: 22944659. doi:10.1515/hsz-2012-0119
   PubMed Web of Science ®Google Scholar
• Xie Y, Liu J, Kang R, Tang D. Mitophagy receptors in tumor biology. Front Cell Dev Biol. 2020;8:594203. PMID: 33262988. doi:10.3389/fcell.2020.594203
   PubMed Web of Science ®Google Scholar
• Yan C, Li T-S. Dual role of mitophagy in cancer drug resistance. Anticancer Res. 2018;38:617–621. PMID: 29374684. doi:10.21873/anticanres.12266
   PubMed Web of Science ®Google Scholar
• Arena G, Valente EM. PINK1 in the limelight: multiple functions of an eclectic protein in human health and disease. J Pathol. 2017;241:251–263. PMID: 27701735. doi:10.1002/path.4815
   PubMed Web of Science ®Google Scholar
• Durcan TM, Fon EA. The three ‘P’s of mitophagy: PARKIN, PINK1, and post-translational modifications. Genes Dev. 2015;29:989–999. PMID: 25995186. doi:10.1101/gad.262758.115
   PubMed Web of Science ®Google Scholar
• Song L, Huang Y, Hou X, et al. PINK1/Parkin-mediated mitophagy promotes resistance to sonodynamic therapy. Cell Physiol Biochem. 2018;49:1825–1839. PMID: 30231241. doi:10.1159/000493629
   PubMedGoogle Scholar
• Denisenko TV, Gogvadze V, Zhivotovsky B. Mitophagy in carcinogenesis and cancer treatment. Discov Oncol. 2021;12:58. PMID: 35201480. doi:10.1007/s12672-021-00454-1
   PubMedGoogle Scholar
• Bellot G, Garcia-Medina R, Gounon P, et al. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol Cell Biol. 2009;29:2570–2581. PMID: 19273585. doi:10.1128/MCB.00166-09
   PubMed Web of Science ®Google Scholar
• Liu K, Lee J, Kim JY, et al. Mitophagy Controls the Activities of Tumor Suppressor p53 to Regulate Hepatic Cancer Stem Cells. Mol Cell. 2017;68:281–292.e5. PMID: 29033320. doi:10.1016/j.molcel.2017.09.022
   PubMed Web of Science ®Google Scholar
• Im E, Yoo L, Hyun M, Shin WH, Chung KC. Covalent ISG15 conjugation positively regulates the ubiquitin E3 ligase activity of parkin. Open Biol. 2016;6:160193. PMID: 27534820. doi:10.1098/rsob.160193
   PubMed Web of Science ®Google Scholar
• Jung J, Zhang Y, Celiku O, et al. Mitochondrial NIX promotes tumor survival in the hypoxic niche of glioblastoma. Cancer Res. 2019;79:5218–5232. PMID: 31488423. doi:10.1158/0008-5472.CAN-19-0198
   PubMed Web of Science ®Google Scholar
• Guan Y, Wang Y, Li B, et al. Mitophagy in carcinogenesis, drug resistance and anticancer therapeutics. Cancer Cell Int. 2021;21:350. PMID: 34225732. doi:10.1186/s12935-021-02065-w
   PubMed Web of Science ®Google Scholar
• Katajisto P, Döhla J, Chaffer CL, et al. Stem cells. Asymmetric apportioning of aged mitochondria between daughter cells is required for stemness. Science. 2015;348:340–343. PMID: 25837514. doi:10.1126/science.1260384
   PubMed Web of Science ®Google Scholar
• Smith AG, Macleod KF. Autophagy, cancer stem cells and drug resistance. J Pathol. 2019;247:708–718. PMID: 30570140. doi:10.1002/path.5222
   PubMed Web of Science ®Google Scholar
• Shen Y-A, Wang C-Y, Hsieh Y-T, Chen Y-J, Wei Y-H. Metabolic reprogramming orchestrates cancer stem cell properties in nasopharyngeal carcinoma. Cell Cycle. 2015;14:86–98. PMID: 25483072. doi:10.4161/15384101.2014.974419
   PubMed Web of Science ®Google Scholar
• Luo M, Shang L, Brooks MD, et al. Targeting breast cancer stem cell state equilibrium through modulation of redox signaling. Cell Metab. 2018;28:69–86.e6. PMID: 29972798. doi:10.1016/j.cmet.2018.06.006
   PubMed Web of Science ®Google Scholar
• O’Neill S, Porter RK, McNamee N, Martinez VG, O’Driscoll L. 2-Deoxy-D-Glucose inhibits aggressive triple-negative breast cancer cells by targeting glycolysis and the cancer stem cell phenotype. Sci Rep. 2019;9:3788. PMID: 30846710. doi:10.1038/s41598-019-39789-9
   PubMed Web of Science ®Google Scholar
• Naik PP, Mukhopadhyay S, Panda PK, et al. Autophagy regulates cisplatin-induced stemness and chemoresistance via the upregulation of CD44, ABCB1 and ADAM17 in oral squamous cell carcinoma. Cell Prolif. 2018;51:e12411. PMID: 29171106. doi:10.1111/cpr.12411
   PubMed Web of Science ®Google Scholar
• Yan C, Luo L, Guo C-Y, et al. Doxorubicin-induced mitophagy contributes to drug resistance in cancer stem cells from HCT8 human colorectal cancer cells. Cancer Lett. 2017;388:34–42. PMID: 27913197. doi:10.1016/j.canlet.2016.11.018
   PubMed Web of Science ®Google Scholar
• Lopez J, Tait SWG. Mitochondrial apoptosis: killing cancer using the enemy within. Br J Cancer. 2015;112:957–962. PMID: 25742467. doi:10.1038/bjc.2015.85
   PubMed Web of Science ®Google Scholar
• Dlugosz PJ, Billen LP, Annis MG, et al. Bcl-2 changes conformation to inhibit Bax oligomerization. EMBO J. 2006;25:2287–2296. PMID: 16642033. doi:10.1038/sj.emboj.7601126
   PubMed Web of Science ®Google Scholar
• Safa AR, Pollok KE. Targeting the Anti-Apoptotic Protein c-FLIP for Cancer Therapy. Cancers. 2011;3:1639–1671. PMID: 22348197. doi:10.3390/cancers3021639
   PubMedGoogle Scholar
• Buccarelli M, D’Alessandris QG, Matarrese P, et al. Elesclomol-induced increase of mitochondrial reactive oxygen species impairs glioblastoma stem-like cell survival and tumor growth. J Exp Clin Cancer Res. 2021;40:228. PMID: 34253243. doi:10.1186/s13046-021-02031-4
   PubMed Web of Science ®Google Scholar